Tags : CheckMate-459

Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459

Tuba Khan June 24, 2019

Shots: The P-III CheckMate-459 study results involve assessing of Opdivo vs sorafenib as a 1L treatment in patients with unresectable hepatocellular carcinoma (HCC) The P-III CheckMate-459 study results demonstrated that […]readmore

Tags : CheckMate-459

Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CheckMate-459

﻿Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459